Table 5.
PPV, NPV, and positivity rates of abbreviated bpMRI (a-bpMRI) according to clinically significant PCa prevalence.
| Prevalence of csPCa (Definition 1) | |||
|---|---|---|---|
| 10% | 5% | 2% | |
| MRI score ≥ 3 | |||
| Pos.rate | 59 (51–67) | 57 (49–65) | 56 (47–64) |
| PPV | 16 (9–25) | 8 (3–16) | 4 (1–10) |
| NPV | 98 (91–100) | 100 (94–100) | 100 (95–100) |
| MRI score ≥ 4 | |||
| Pos. rate | 40 (32–49) | 37 (30–46) | 36 (29–45) |
| PPV | 21 (12–34) | 11 (4–22) | 5 (1–15) |
| NPV | 98 (92–100) | 99 (94–100) | 100 (96–100) |
| T2WI and DWI score ≥ 4 | |||
| Pos. rate | 26 (19–34) | 23 (17–31) | 22 (16–29) |
| PPV | 28 (15–45) | 14 (5–30) | 6 (1–20) |
| NPV | 96 (91–99) | 98 (94–100) | 99 (95–100) |
Values are reported as % (95%—CI). Pos. rate: rate of positive test according to MRI cut-off. csPCa: clinically significant prostate cancer; pos. rate: positivity rate of MRI; PPV: positive predictive value; NPV: negative predictive value.